Retatrutide 30mg FlexiPen

Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide that activates three metabolic receptors: GLP-1 (glucagon-like peptide 1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This tri-receptor mechanism is the basis for the compound being studied as one of the most potent investigational research compounds in this class.

In the 2023 Phase 2 trial published in the *New England Journal of Medicine*, the 12-mg retatrutide group had a least-squares mean body-weight change of −24.2% at 48 weeks, compared with −2.1% with placebo. In the completed Phase 3 TRIUMPH-1 trial, Lilly’s May 2026 topline results showed average weight changes at 80 weeks of −19.0% with 4mg, −25.9% with 9mg, and −28.3% with 12mg, compared with −2.2% with placebo. In a prespecified 104-week extension among participants with baseline BMI ≥35, the 12-mg group reached an average −30.3% weight change. These Phase 3 figures are sponsor-reported topline results pending full peer-reviewed publication. Retatrutide remains investigational.

Retatrutide is the only compound that attacks the energy balance equation from both sides: reducing appetite through GLP-1 and GIP activity, while simultaneously increasing energy expenditure and fat oxidation through glucagon receptor activation.

Pre-filled pen format.

Most suppliers sell Retatrutide as lyophilized powder in vials. That means you need bacteriostatic water, syringes, and the knowledge to reconstitute correctly. One mistake and you compromise the product or the dose. Our 30mg FlexiPen is pre-filled, pre-mixed, and ready to use. Dial your dose, click, done.

≥99% purity, Janoshik verified.

Every batch is independently tested by Janoshik, the most recognized third-party peptide testing laboratory in the world. We test for identity confirmation via liquid chromatography-mass spectrometry, purity via HPLC, endotoxin levels, sterility, heavy metals, and net peptide content. We publish every report. No in-house certificates of analysis. No trust-me claims. Verified data you can check yourself.

Research-grade packaging.

Every order ships with the pen device, 20 sterile pen needles (31G, 5mm), and a product information insert with full dosing guidance. Outer carton, sealed needle box, cold-chain packaging.

Same-day Dubai delivery.

Orders placed before 4 PM ship same day within Dubai. Outside Dubai, order before 12 PM (noon) for next-day delivery. Orders placed on Saturday will be delivered on Monday, and Sunday delivery is not available outside Dubai. Delivery costs AED 50 below AED 1,000 and is free from AED 1,000. Cold-chain maintained from our facility to your door.

Stabilized and pH-balanced formula.

We are the only brand that sells Retatrutide in a stabilized, pH-balanced solution. This means the peptide degrades significantly slower and stays effective for longer compared to standard reconstituted vials. Our formulation contains m-Cresol, a preservative used in licensed pen products. You can actually smell it when you uncap the pen: a faint, distinct medicinal scent that tells you you are dealing with a properly formulated product, not peptide powder dissolved in water.

Manufactured by Remedium Research.

The Retatrutide 30mg FlexiPen is manufactured by Remedium Research, the specialist peptide laboratory behind the most widely used pre-filled retatrutide pen format globally. ProPeptide is an authorised Remedium Research reseller in the UAE. Every pen ships directly from Remedium Research production to our facility.

No middlemen.

We source directly from Remedium Research and control every step from production to delivery. No clinic markups, no distributor margins, no mystery supply chains.

Retatrutide activates three receptor pathways simultaneously. No other metabolic compound does this.

GLP-1 (glucagon-like peptide 1) receptor

Promotes satiety signaling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. This is the same pathway targeted by semaglutide and by the GLP-1 component of tirzepatide.

GIP (glucose dependent insulinotropic polypeptide) receptor

Enhances insulin response after meals, has direct effects on adipose tissue, and works synergistically with GLP-1 to amplify metabolic signaling. This is the second pathway targeted by tirzepatide, making it a dual agonist. Retatrutide includes this plus a third target.

Glucagon receptor

Increases resting energy expenditure, promotes hepatic lipid oxidation, and mobilizes stored fat for fuel. This is the component that distinguishes Retatrutide from every other metabolic compound. Semaglutide and tirzepatide do not activate the glucagon receptor at all.

The combined action of all three pathways produces greater metabolic effects than any single or dual agonist compound, as documented in research published in the *New England Journal of Medicine*.

The ProPeptide FlexiPen allows precise click-dose adjustment. Use this progression as the dosing reference.